ACM
ADAR1 Capital Management Portfolio holdings
AUM
$2.19B
Turnover
34.18%
1-Year Est. Return
374.99%
This Fund
S&P 500
This Quarter
Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
(+29%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
7.61%
Top 10 Holdings %
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9
years
Top 10 Avg Time Held Equity + Options
1.1
years
Top 20 Avg Time Held Equity + Options
0.9
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
1.3
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$46.5M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$38.5M |
| 3 |
Zai Lab
ZLAB
|
+$38.4M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$34.8M |
| 5 |
Editas Medicine
EDIT
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$48.2M |
| 2 |
Beam Therapeutics
BEAM
|
+$34.5M |
| 3 |
Scholar Rock
SRRK
|
+$20M |
| 4 |
Denali Therapeutics
DNLI
|
+$17.3M |
| 5 |
Cytokinetics
CYTK
|
+$12.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.67% |
| 2 | Miscellaneous | 11.02% |
| 3 | Financials | 2.15% |
| 4 | Real Estate | 0.05% |
| 5 | Communication Services | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
C4 Therapeutics
CCCC
$321M
| $1.36M | 0.06% |
291,957
+248,957
| +579% | +$852K |
2026 Q1
1 quarter
|
|
152
BioCryst Pharmaceuticals
BCRX
$2.06B
| $1.33M | 0.06% |
133,000
+28,000
| +27% | +$253K |
2025 Q4
2 quarters
|
|
153
Supernus Pharmaceuticals
SUPN
$2.34B
| $1.29M | 0.06% |
27,842
-1,800
| -6% | -$86.5K |
2025 Q3
3 quarters
|
|
154
Novo Nordisk
NVO
$168B
| $1.29M | 0.06% |
27,000
-6,000
| -18% | -$258K |
2026 Q1
1 quarter
|
|
155
Avantor
AVTR
$10.6B
| $1.29M | 0.06% |
130,000
+50,000
| +63% | +$430K |
2025 Q2
4 quarters
|
|
156
InMed Pharmaceuticals
INM
$7.2M
| $1.24M | 0.06% |
+800,000
| New | +$884K |
2026 Q2
0 quarters
|
|
157
ProMIS Neurosciences
PMN
$74.3M
| $1.22M | 0.06% |
92,850
-2,500
| -3% | -$27.1K |
2026 Q1
1 quarter
|
|
158
Artiva Biotherapeutics
ARTV
$289M
| $1.15M | 0.05% |
+118,624
| New | +$1.08M |
2026 Q2
0 quarters
|
|
159
Tenaya Therapeutics
TNYA
$87.6M
| $1.15M | 0.05% |
1,555,500
+47,700
| +3% | +$36.2K |
2025 Q4
2 quarters
|
|
160
ALX Oncology
ALXO
$124M
| $1.1M | 0.05% |
+533,660
| New | +$955K |
2026 Q2
0 quarters
|
|
161
Alexandria Real Estate Equities
ARE
$7.14B
| $1.03M | 0.05% |
19,500
| – | – |
2025 Q4
2 quarters
|
|
162
Cartesian Therapeutics
RNAC
$192M
| $1.03M | 0.05% |
+98,877
| New | +$732K |
2026 Q2
0 quarters
|
|
|
KRSA
163
Korsana Biosciences, Inc. Common Stock
KRSA
$1.56B
| $1.01M | 0.05% |
+42,680
| New | +$969K |
2026 Q2
0 quarters
|
|
164
DELISTED
Electronic Arts
EA
| $1.01M | 0.05% |
4,936
| – | – |
2025 Q3
3 quarters
|
|
165
BioNTech
BNTX
$22.3B
| $986K | 0.05% |
10,600
+600
| +6% | +$56.5K |
2025 Q3
3 quarters
|
|
166
Acadia Pharmaceuticals
ACAD
$3.32B
| $986K | 0.05% |
+38,955
| New | +$857K |
2026 Q2
0 quarters
|
|
167
Dyne Therapeutics
DYN
$2.81B
| $951K | 0.04% |
42,821
-4,642
| -10% | -$86.3K |
2025 Q1
5 quarters
|
|
168
MapLight Therapeutics
MPLT
$434M
| $950K | 0.04% |
26,497
-348,412
| -93% | -$10M |
2026 Q1
1 quarter
|
|
169
Structure Therapeutics
GPCR
$1.56B
| $939K | 0.04% |
+17,500
| New | +$774K |
2026 Q2
0 quarters
|
|
170
CALL
DELISTED
Keen Vision Acquisition Corp
KVAC
| $930K | 0.04% |
75,000
| – | – |
2025 Q3
3 quarters
|
|
171
Wave Life Sciences
WVE
$609M
| $930K | 0.04% |
160,000
+115,100
| +256% | +$763K |
2026 Q1
1 quarter
|
|
172
Aura Biosciences
AURA
$640M
| $924K | 0.04% |
+130,152
| New | +$931K |
2026 Q2
0 quarters
|
|
173
Churchill Capital Corp XI
CCXI
$603M
| $873K | 0.04% |
+50,000
| New | +$532K |
2026 Q2
0 quarters
|
|
174
Kazia Therapeutics
KZIA
$106M
| $867K | 0.04% |
+61,550
| New | +$750K |
2026 Q2
0 quarters
|
|
175
DELISTED
Nuvalent
NUVL
| $857K | 0.04% |
6,942
| – | – |
2025 Q2
4 quarters
|
|
Similar funds
GAMH
RCAG
AF
AWM
TCM
WRBC
IAN
BOI
ADAR1 Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.
- ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
- ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
- ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
- ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
- ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
- ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
- ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.
Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.